Abstract:
Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of H. pylori in the metropolitan area and examined factors concerning successful eradication. Methods:We collected data from 20 hospitals in the Tokyo metropolitan area on patients who received first-line eradication therapy with a proton-pump inhibitor (PPI)/P-CAB, amoxicillin, and clarithromycin for 1 week and second-line eradication therapy with a PPI/P-CAB, amoxicillin, and metronidazole for 1 week from 2013 to 2018. The annual eradication rate and associated factors for successful eradication were analyzed. Results:We collected data of 4097 and 3572 patients in the first- and second-line eradication therapies, respectively. The eradication rate decreased from 2013 to 2014 and increased again from 2015 to 2018 with the first-line therapy [the eradication rates in 2013, 2014, 2015, 2016, 2017 and 2018 were 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1%, respectively, in the per protocol (PP)]. The second-line eradication rates were 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in 2013, 2014, 2015, 2016, 2017 and 2018, respectively, in PP. Vonoprazan was an independent factor for successful eradication in not only first-line, but also second-line eradication. Age over 75 years was an independent factor for eradication failure in both first- and second-line eradication therapies. Conclusion:The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients.
journal_name
Therap Adv Gastroenteroljournal_title
Therapeutic advances in gastroenterologyauthors
Mori H,Suzuki H,Omata F,Masaoka T,Asaoka D,Kawakami K,Mizuno S,Kurihara N,Nagahara A,Sakaki N,Ito M,Kawamura Y,Suzuki M,Shimada Y,Sasaki H,Matsuhisa T,Torii A,Nishizawa T,Mine T,Ohkusa T,Kawai T,Tokunaga K,Takdoi
10.1177/1756284819858511subject
Has Abstractpub_date
2019-07-04 00:00:00pages
1756284819858511eissn
1756-283Xissn
1756-2848pii
10.1177_1756284819858511journal_volume
12pub_type
杂志文章abstract::Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X16658251
更新日期:2016-11-01 00:00:00
abstract:Background:Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potenti...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818785573
更新日期:2018-07-16 00:00:00
abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16672392
更新日期:2017-01-01 00:00:00
abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11413315
更新日期:2011-11-01 00:00:00
abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 已发布勘误
doi:10.1177/1756283X10363751
更新日期:2012-09-01 00:00:00
abstract:Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD. Methods:This was a tw...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819842756
更新日期:2019-04-17 00:00:00
abstract::Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X13508519
更新日期:2014-03-01 00:00:00
abstract::The human gastrointestinal tract comprises a series of complex and dynamic organs ranging from the stomach to the distal colon, which harbor immense microbial assemblages that are known to be vital for human health. Until recently, most of the details concerning our gut microbiota remained obscure. Over the past sever...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09337646
更新日期:2009-07-01 00:00:00
abstract::Severe acute pancreatitis (SAP) is a critical abdominal disease associated with high death rates. A systemic inflammatory response promotes disease progression, resulting in multiple organ dysfunction. The functions of neutrophils in the pathology of SAP have been presumed traditionally to be activation of chemokine a...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820974913
更新日期:2020-11-24 00:00:00
abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17722061
更新日期:2017-10-01 00:00:00
abstract:BACKGROUND:Dual red imaging (DRI), a novel image-enhanced endoscopic technique, is expected to improve visibility of thin vessels, but no reports of the clinical use of DRI in colorectal endoscopic submucosal dissection (ESD) have been published. We aimed to compare the visibility of vessels, demarcation line between t...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16645501
更新日期:2016-09-01 00:00:00
abstract::Sex-based differences in inflammatory bowel disease (IBD) pathogenesis, disease course, and response to therapy have been increasingly recognized, however, not fully understood. Experimental and translational models have been leveraged to investigate hypothesized mechanisms for these observed differences, including th...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820915043
更新日期:2020-04-28 00:00:00
abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820938960
更新日期:2020-07-16 00:00:00
abstract::The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incide...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820931739
更新日期:2020-07-09 00:00:00
abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819884418
更新日期:2019-10-24 00:00:00
abstract::Faecal incontinence, defined as the involuntary loss of solid or liquid stool, is a common problem affecting 0.8-8.3% of the adult population. Individuals suffering from faecal incontinence often live a restricted life with reduced quality of life. The present paper is a clinically oriented review of the pathophysiolo...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15614516
更新日期:2016-01-01 00:00:00
abstract::Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11428502
更新日期:2012-03-01 00:00:00
abstract::Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X16638833
更新日期:2016-07-01 00:00:00
abstract::Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15587481
更新日期:2015-09-01 00:00:00
abstract::The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17694832
更新日期:2017-05-01 00:00:00
abstract:Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819843002
更新日期:2019-04-10 00:00:00
abstract::The wireless motility capsule (WMC) is an ambulatory noninvasive and nonradioactive diagnostic sensor that continuously samples intraluminal pH, temperature, and pressure as it moves through the gastrointestinal (GI) tract. This review summarizes the data obtained in clinical trials with the WMC and discusses its role...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12437874
更新日期:2012-07-01 00:00:00
abstract:Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284818814948
更新日期:2018-12-06 00:00:00
abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X08094880
更新日期:2008-09-01 00:00:00
abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11410770
更新日期:2011-09-01 00:00:00
abstract::Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819832237
更新日期:2019-04-02 00:00:00
abstract::The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346669
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosph...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16673981
更新日期:2017-04-01 00:00:00
abstract::Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutati...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12467565
更新日期:2013-03-01 00:00:00
abstract::Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283x08103341
更新日期:2009-01-01 00:00:00